Therefore, molecular validation of meningioma findings (e.g., NF2, AKT1, TRAF7) and an increase in both sample size and tumour subtype diversity are important for enhancing the reliability and generalizability of future studies. This evidence concerns the gene AKT1 and neoplasm.